Life Sciences & Healthcare

We guide biotech, healthcare, medtech, and pharmaceutical enterprises—public and private, large and small—in solving their legal problems at every stage of growth. We offer experienced guidance through the sector’s complex regulatory, transactional, operational, financial, and compliance issues and disputes.

Life sciences and healthcare organizations depend on experienced representation in business, legal, and regulatory matters. Our biotechnology and pharmaceutical teams support clients developing and commercializing products and services that diagnose, prevent, and treat disease. We also advise clients in the medical device and medtech sectors on technologies spanning cardiovascular, diabetes, gastroenterology, imaging systems, implants, neurology, optics, pain management, renal care, stimulation devices, and surgical tools.

We are an innovation partner to clients, helping them grow from the ground up to publicly traded Fortune 500 companies. Our lawyers counsel clients on intellectual property matters, fundraising, strategic alliances, collaborations, licenses, and other technology transactions, beginning with early-stage companies.

We advise healthcare providers and organizations, hospitals, insurers, research institutions, and companies throughout the industry on digital health services, FDA and controlled substance issues, transactions, managed care, litigation, operations and policy, regulatory compliance, reimbursement, data privacy and security, contracts and associated disputes, internal investigations, government audits and investigations, antitrust, tax, M&A, and real estate.

Our IP team offers boutique capabilities within a global, full-service firm. With a proven track record, we represent pharmaceutical and biotechnology clients in complex, high-stakes patent litigation in federal district courts across the United States and before the U.S. Court of Appeals for the Federal Circuit and U.S. International Trade Commission. We guide clients through inter partes review, ex parte reexamination, derivation, and interference proceedings before the U.S. Patent Trial and Appeal Board (PTAB), and we prosecute and manage patent portfolios. Furthermore, we counsel pharmaceutical companies on regulatory strategies and all aspects of the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA). Our global presence allows us to assemble strong teams around the world.